Europe Anticoagulation Therapy Market, By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke and Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists and Others), Drug Type (Bivalirudin, Dabigatran, Edoxaban, Betrixaban, Rivaroxaban, Apixaban, Enoxaparin, Dalteparin and Others), Route of Administration (Oral and Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS and Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis and Heart Valve Replacement), Type (Generics and Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Country (Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey and Rest of Europe) Industry Trends and Forecast to 2028.
Data Bridge Market Research analyses that the anticoagulation therapy will exhibit a CAGR of around 8.40% for the forecast period of 2021-2028. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of novel drugs and therapies, increasing prevalence of arrhythmia and other chronic disorders and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of anticoagulation therapy market.
Anticoagulation therapy is the use of drugs that is used to prevent or reduce the coagulation of blood. Anticoagulant therapy is generally used for high risk of blood clots in various medical conditions. Anticoagulants are generally called as blood thinners.
Ever-rising geriatric population base coupled with growing prevalence of blood vessel thromboembolism and stroke is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing number of road accidents, increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders and upsurge in the diagnosis rate among the market players are other factors also fostering the growth of the market. Increasing adoption of novel oral anticoagulants (NOACs) is other indirect determinant that will create lucrative market growth opportunities.
However, unfavourable reimbursement scenario in the developing and under developed economies will pose a major challenge to the market growth. Also, high costs associated with research and development proficiencies will further derail the market growth rate. Lack of awareness in the underdeveloped and backward economies, higher price of NOACs, lack of antidotes for NOACs and availability of alternative therapies will also hamper the market growth rate.
This anticoagulation therapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on anticoagulation therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Anticoagulation Therapy Market Scope and Market Size
The anticoagulation therapy market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the anticoagulation therapy market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others.
- On the basis of therapeutic class, the anticoagulation therapy market is segmented into novel oral anticoagulants (noac), heparin, vitamin k antagonists and others.
- Based on drug type, the anticoagulation therapy market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others.
- On the basis of route of administration, the anticoagulation therapy market is segmented into oral and Injectable.
- Based on therapeutic area, the anticoagulation therapy market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others.
- On the basis of procedure, the anticoagulation therapy market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement.
- On the basis of type, the anticoagulation therapy market is segmented into generics and branded.
- The end user segment of anticoagulation therapy market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others.
- Based on distribution channel, the anticoagulation therapy market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Anticoagulation Therapy Market Country Level Analysis
The anticoagulation therapy market is analysed and market size insights and trends are provided by country, treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the anticoagulation therapy market report are Germany, U.K, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey and Rest of Europe.
U.K., France and Germany in Europe region dominate the anticoagulation therapy market owing to the earliest adoption of advanced healthcare technologies, growing prevalence of arrhythmia, growing adoption of blood thinning medications and presence of a favourable reimbursement scenario.
The country section of the anticoagulation therapy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The anticoagulation therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Anticoagulation Therapy Market Share Analysis
The anticoagulation therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to anticoagulation therapy market.
The major players covered in the anticoagulation therapy market report are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo International plc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., and Taro Pharmaceutical Industries Ltd. among other. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.